Liron Hofstetter

Tel Aviv, TA, Israel

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First-Line Ibrutinib-Venetoclax.

Cardiac Adverse Events in Patients With Chronic Lymphocytic Leukemia Treated With First-Line Ibrutinib-Venetoclax.

Journal: European journal of haematology
Published: June 17, 2026

Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.

Real-World Outcomes of Venetoclax-Based Therapy in Treatment-Naïve and Relapsed/Refractory CLL/SLL: Interim Results From the Prospective REVEAL Study.

Journal: American journal of hematology
Published: April 09, 2026

Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study.

Pericardial effusion and tamponade as a rare cardiac toxicity of covalent BTK inhibitors in CLL-a multi-modality study.

Journal: Leukemia & lymphoma
Published: January 26, 2026

Low-normal immunoglobulin suggests monoclonal B-cell lymphocytosis and constitutional CLL susceptibility: a dual-mechanism analysis.

Low-normal immunoglobulin suggests monoclonal B-cell lymphocytosis and constitutional CLL susceptibility: a dual-mechanism analysis.

Journal: Leukemia
Published: January 19, 2026

Low serum IgE is associated with an increased risk of chronic lymphocytic leukemia: a large retrospective cohort study.

Low serum IgE is associated with an increased risk of chronic lymphocytic leukemia: a large retrospective cohort study.

Journal: Frontiers in immunology
Published: December 21, 2025

Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.

Infectious complications in CLL/SLL patients receiving Bruton's Tyrosine Kinase inhibitors - systematic review and meta-analysis of randomized controlled trials.

Journal: Annals of hematology
Published: May 13, 2025

A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.

A retrospective study of 222 patients with newly diagnosed primary central nervous system lymphoma-Outcomes indicative for improved survival overtime.

Journal: Hematological oncology
Published: March 19, 2023

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.

CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.

Journal: Journal of clinical medicine
Published: April 15, 2022

Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.

Evaluating outcomes of adult patients with acute lymphoblastic leukemia and lymphoblastic lymphoma treated on the GMALL 07/2003 protocol.

Journal: Annals of hematology
Published: July 15, 2021

An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis.

An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis.

Journal: Blood
Published: May 31, 2021

Post-transplantation erythrocytosis in kidney transplant recipients-A retrospective cohort study.

Post-transplantation erythrocytosis in kidney transplant recipients-A retrospective cohort study.

Journal: European journal of haematology
Published: May 22, 2021

Challenges and Advances in Managing Thrombocytopenic Cancer Patients.

Challenges and Advances in Managing Thrombocytopenic Cancer Patients.

Journal: Journal of clinical medicine
Published: January 31, 2021
Showing 1-12 of 15

Last Updated: 09/26/2026